U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 179

1.
Aprepitant Restores Corneal Sensitivity and Reduces Pain in DED
Filippo Bonelli, Fabiola Campestre, Romina Mayra Lasagni Vitar, Ibrahim Halil Demirsoy, Philippe Fonteyne, Giulio Ferrari
Transl Vis Sci Technol. 2024 Feb; 13(2): 9. Published online 2024 Feb 12. doi: 10.1167/tvst.13.2.9
PMCID:
PMC10866158
AbstractArticlePDF–1.9M
2.
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting
Bernardo Leon Rapoport, Jørn Herrstedt, Rebecca Clark Snow, Venkatraman Radhakrishnan, Mitsue Saito, Rudolph M. Navari, Teresa Smit
Support Care Cancer. 2024; 32(1): 36. Published online 2023 Dec 18. doi: 10.1007/s00520-023-08224-1
PMCID:
PMC10725845
AbstractArticlePDF–484K
3.
Assessing the impact of aprepitant and ondansetron on postoperative nausea and vomiting in orthognathic surgeries: a randomized controlled trial
Mostafa Alam, Alireza Shakeri, Ardeshir Khorsand, Karim Nasseri, Sadaf Nasseri
BMC Anesthesiol. 2023; 23: 412. Published online 2023 Dec 13. doi: 10.1186/s12871-023-02371-y
PMCID:
PMC10717277
AbstractArticlePDF–841K
4.
Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: A meta-analysis
Min Zhang, Qing-Li Guo, Ting-Ting Zhang, Min Fu, Heng-Tai Bi, Jun-Yao Zhang, Kai-Li Zou
Medicine (Baltimore) 2023 Nov 24; 102(47): e35952. Published online 2023 Nov 24. doi: 10.1097/MD.0000000000035952
PMCID:
PMC10681589
AbstractArticlePDF–1.8M
5.
The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: A meta-analysis
Yingchao Liu, Xinli Chen, Xiaohua Wang, Huohu Zhong, Hefan He, Yibin Liu, Yuewen Liao, Zhigang Pan, Weipeng Hu, Weifeng Liu, Feng Zheng
Medicine (Baltimore) 2023 Jul 21; 102(29): e34385. Published online 2023 Jul 21. doi: 10.1097/MD.0000000000034385
PMCID:
PMC10662847
AbstractArticlePDF–1.3M
6.
The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant
Rafael Coveñas, Francisco D. Rodríguez, Prema Robinson, Miguel Muñoz
Int J Mol Sci. 2023 Nov; 24(21): 15936. Published online 2023 Nov 3. doi: 10.3390/ijms242115936
PMCID:
PMC10650658
AbstractArticlePDF–1.0M
7.
A randomized trial evaluating the association between related gene polymorphism and nausea and vomiting induced by cisplatin multi-day chemotherapy
Yilan Jin, Feng Chen, Juan Zhao, Ying Jiang, Gaowa Jin, Zewei Zhang, Quanfu Li
BMC Med Genomics. 2023; 16: 276. Published online 2023 Nov 3. doi: 10.1186/s12920-023-01719-0
PMCID:
PMC10625179
AbstractArticlePDF–1.2M
8.
The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive
Richard E. Kast
Int J Mol Sci. 2023 Oct; 24(20): 15474. Published online 2023 Oct 23. doi: 10.3390/ijms242015474
PMCID:
PMC10607234
AbstractArticlePDF–1.0M
9.
Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
Laurent Zelek, Rudolph Navari, Matti Aapro, Florian Scotté
Cancer Med. 2023 Aug; 12(15): 15769–15776. Published online 2023 Aug 3. doi: 10.1002/cam4.6121
PMCID:
PMC10469631
AbstractArticlePDF–365K
10.
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)
Rudolph M Navari, Jennifer Le-Rademacher, Fabrice Smieliauskas, Kathryn J Ruddy, Thomas James Saphner, Heshan Liu, Elizabeth Harlos, Adedayo A Onitilo, Karthik Giridhar, Preet Paul Singh, Pavan S Reddy, Selina Chow, Flavio Kruter, George Raptis, Charles L Loprinzi
Oncologist. 2023 Aug; 28(8): 722–729. Published online 2023 Jun 7. doi: 10.1093/oncolo/oyad140
PMCID:
PMC10400142
AbstractArticlePDF–735K
11.
Asymmetric Catalytic Access to Piperazin-2-ones and Morpholin-2-ones in a One-Pot Approach: Rapid Synthesis of an Intermediate to Aprepitant
Sara Meninno, Alessandra Lattanzi
J Org Chem. 2023 Jun 16; 88(12): 7888–7892. Published online 2023 Feb 21. doi: 10.1021/acs.joc.2c02491
PMCID:
PMC10278953
AbstractArticlePDF–1.5M
12.
Aprepitant inhibits the progression of esophageal squamous cancer by blocking the truncated neurokinin‑1 receptor
Yang Zheng, Meixiang Sang, Fei Liu, Lina Gu, Juan Li, Yunyan Wu, Baoen Shan
Oncol Rep. 2023 Jul; 50(1): 131. Published online 2023 May 9. doi: 10.3892/or.2023.8568
PMCID:
PMC10236268
AbstractArticlePDF–11M
13.
Therapeutic antagonism of the neurokinin 1 receptor in endosomes provides sustained pain relief
Alan Hegron, Chloe J. Peach, Raquel Tonello, Philipp Seemann, Shavonne Teng, Rocco Latorre, Harald Huebner, Dorothee Weikert, Jeanette Rientjes, Nicholas A. Veldhuis, Daniel P. Poole, Dane D. Jensen, Alex R. B. Thomsen, Brian L. Schmidt, Wendy L. Imlach, Peter Gmeiner, Nigel W. Bunnett
Proc Natl Acad Sci U S A. 2023 May 30; 120(22): e2220979120. Published online 2023 May 22. doi: 10.1073/pnas.2220979120
PMCID:
PMC10235985
AbstractArticlePDF–8.3M
14.
Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation
Xueyan Cao, Yang Yang, Wei Zhou, Yue Wang, Xue Wang, Xianxiu Ge, Fei Wang, Fangfang Zhou, Xueting Deng, Lin Miao
BMC Cancer. 2023; 23: 471. Published online 2023 May 23. doi: 10.1186/s12885-023-10954-8
PMCID:
PMC10204192
AbstractArticlePDF–13M
15.
Sustained endosomal release of a neurokinin-1 receptor antagonist from nanostars provides long-lasting relief of chronic pain
Rocco Latorre, Paulina D. Ramírez-Garcia, Alan Hegron, James L. Grace, Jeffri S. Retamal, Priyank Shenoy, Mai Tran, Luigi Aurelio, Bernard Flynn, Daniel P. Poole, Rafael Klein-Cloud, Dane D. Jensen, Thomas P. Davis, Brian L. Schmidt, John F. Quinn, Michael R. Whittaker, Nicholas A. Veldhuis, Nigel W. Bunnett
Biomaterials. Author manuscript; available in PMC 2023 Jun 1.
Published in final edited form as: Biomaterials. 2022 Jun; 285: 121536. Published online 2022 Apr 28. doi: 10.1016/j.biomaterials.2022.121536
PMCID:
PMC10064865
AbstractArticlePDF–3.6M
16.
Preparation and in vivo evaluation of an intravenous emulsion loaded with an aprepitant-phospholipid complex
Yan Li, Hong Yin, Chensi Wu, Jia He, Chunyan Wang, Bo Ren, Heping Wang, Dandan Geng, Yirong Zhang, Ligang Zhao
Drug Deliv. 2023; 30(1): 2183834. Published online 2023 Feb 27. doi: 10.1080/10717544.2023.2183834
PMCID:
PMC9979997
AbstractArticlePDF–1.8M
17.
Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin
Yuanyuan Zhao, Bing Zhao, Gang Chen, Yinlan Chen, Zijun Liao, Haiming Zhang, Weineng Feng, Yinyin Li, Heng Weng, Weidong Li, Yuefen Zhou, Biyong Ren, Yanda Lu, Jianhua Chen, Zhenteng Liu, Zhenzhong Su, Wenliang Wang, Li Zhang
Cancer Commun (Lond) 2023 Feb; 43(2): 246–256. Published online 2022 Dec 22. doi: 10.1002/cac2.12397
PMCID:
PMC9926955
AbstractArticlePDF–960K
18.
What percentage of patients with cancer develop hiccups with oxaliplatin- or cisplatin-based chemotherapy? a compilation of patient-reported outcomes
Christopher Ehret, Nichole A. Martin, Aminah Jatoi
PLoS One. 2023; 18(1): e0280947. Published online 2023 Jan 27. doi: 10.1371/journal.pone.0280947
PMCID:
PMC9882886
AbstractArticlePDF–561K
19.
Potential therapeutic effect of NK1R antagonist in diabetic non-healing wound and depression
Mingyu Li, Hao Ma, Shunuo Zhang, Yuan Peng, Liang Ding, Yixin Zhang, Peiru Min
Front Endocrinol (Lausanne) 2022; 13: 1077514. Published online 2023 Jan 4. doi: 10.3389/fendo.2022.1077514
PMCID:
PMC9845920
AbstractArticlePDF–5.4M
20.
Cardioprotective action of aprepitant in a rat model of ischemia-reperfusioninduced myocardial injury: role of PI3K-AkT-GSK-3β-HIF-1α signaling pathway
Mei Qian, Yang Liu
Acta Cir Bras. 2022; 37(10): e371004. Published online 2022 Dec 19. doi: 10.1590/acb371004
PMCID:
PMC9762430
AbstractArticlePDF–308K

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

You are here: NCBI > Literature > PubMed Central (PMC)
Support Center